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I. INTRODUCTION
Significant advancements are being made in agricultural bio-
technology.' New advancements in genetic engineering and
testing methods have resulted in easier identification of differ-
ent plant varieties and have promoted the development of
transgenic plants and animals. 2 The intellectual property
t Partner, Lord, Bissell & Brook, Chicago, Illinois.
1. Biotechnology is "any technique that uses living organisms (or parts of orga-
nisms) to make or modify products, to improve plants or animals, or to develop mi-
croorganisms for specific uses." JACK R. KLOPPENBURG, JR., FIRST THE SEED: THE
POLITICAL ECONOMY OF PLANT BIOTECHNOLOGY 1492-2000 (1988) (using the Con-
gressional Office of Technology Assessment's definition of biotechnology).
2. A transgenic plant is "a plant which is transformed when a gene taken di-
rectly from another plant or organism is physically inserted into it." John
Schoenemann, Transgenic Plants May Be In Your Future, AMERICAN VEGETABLE GROWER,
1
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rights in the new processes and products of biotechnology can
be protected. For example, plants are now subject to general
utility patent, as well as Plant Patent Act, Plant Variety Protec-
tion Act, and trade secret protection. Courts have recently de-
cided several important cases pertaining to the protection of
plant varieties and processes.
Government regulation of agricultural biotechnology con-
tinues to be an area of uncertainty. Although the United States
Department of Agriculture, the Environmental Protection
Agency and the Food and Drug Administration all have a hand
in the current regulatory structure, the agencies' individual
roles have not been well defined. The new administration,
particularly Vice-President Albert Gore, has expressed an in-
terest in reviewing the existing regulatory framework and po-
tentially proposing changes in the present regulatory scheme.4
This Article will discuss recent developments in agricultural
biotechnology. Additionally, the Article will discuss the appli-
cability of patent and trade secret protection to agricultural de-
velopments and current government regulation of agricultural
biotechnology. Finally, the Article examines the subject of fu-
ture regulation.
II. SIGNIFICANT DEVELOPMENTS IN ANIMAL AND PLANT
BIOTECHNOLOGY
A. Animal Biotechnology
Developments in animal agriculture are proceeding at a
somewhat different pace than developments in plant biotech-
nology.5 Desired changes in animals can still be made rela-
Aug. 1992, at 21-22. See also Boyee Rensberger, Technique May Fight Disease by Revers-
ing Instructions to Cells, WASH. POST, Jan. 4, 1993, at A3 (containing a description of
how a transgenic plant is formed).
3. See infra Part III.B.
4. Vice-President Gore has shown a great interest in the subject during his
terms in the Senate and in the House. In his recent book, Vice-President Gore pro-
posed the development of a Strategic Environment Initiative to discourage and phase
out older technologies. Gore also called for the development of a new generation of
environmentally benign substitutes. AL GORE, EARTH IN THE BALANCE 140, 319
(1992). See also Alex Barnum, Biotech Poses Key Test for Clinton Administration: New Lead-
ership Faces a Balancing Act Between the Environmental and High-Tech Sectors, SAN. FRAN.
CHRON., Jan. 4, 1993, at BI (discussing possible action of Clinton administration in
biotechnology industry).
5. John M. Czarnetzky, Altering Nature's Blueprint for Profit Patenting Multicellular
Animals, 74 VA. L. REV. 1327, 1329-30 (1988).
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tively quickly through conventional breeding and selection
techniques. 6 In just a few years, size, muscling, and conforma-
tion traits can be bred into large numbers of animals to signifi-
cantly alter the attributes of any breed.
While advancement in the genetic engineering of animals
has not yet progressed to the levels achieved in plant research,
transgenic animals are on the horizon.7 Ethical concerns that
have slowed the short term progress may continue into the
near future.8 Among these ethical concerns are human control
of life, maintenance of species integrity, and economic equity.9
Because many of these arguments predate patenting animal
technology it is unclear what, if any, new issues patenting will
add to these ethical concerns.' 0
B. Plant Biotechnology
1. Identification and Labeling of Plant Varieties
The identification and labeling of plant varieties is an impor-
tant issue for the seed industry, the government, and farm-
ers."1 Proper labeling is essential to maintain fair competition
and to prevent misrepresentation of seed varieties.12 The Fed-
eral Seed Act, enacted in 1939,'1 and regulations promulgated
under the Act,' 4 require labeling by varietal name. These reg-
6. Daniel D. Jones, Genetic Engineering in Domestic Food Animals: Legal and Regula-
tory Considerations, 38 FooD DRUG CosM. L.J. 273 (1983).
7. In 1988, the United States Patent Office granted Patent No. 4,736,866, the
first patent for a multi-cellular animal. The patent was granted to a team of research-
ers who had developed a genetically altered mouse to aid their research in breast
cancer. See Czarnetzky, supra note 5, at 1327 (discussing the patenting of multicellu-
lar animals). See also infra notes 78-80 and accompanying text.
8. See Kevin W. O'Connor, Patenting Animals and Other Living Things, 65 S. CAL. L.
REV. 597, 613-14 (1991); Czarnetzky, supra note 5, at 1328 n.5; Mark W. Lauroesch,
Note, Genetic Engineering: Innovation and Risk Minimization, 57 GEO. WASH. L. REV. 100,
114-19 (1988).
9. See O'Connor, supra note 8, at 613.
10. Id. at 614.
11. See Roy G. Creech, Federal Seed Program Review 49 (United States Department
of Agriculture, Final Report, Sept. 30, 1980).
12. Roy Creech notes that one problem in variety identification and labeling is
that there is no agreement on what constitutes a variety. Id. Varietal mislabeling is
not a new problem. For example, prior to the 1950's, hybrid seed corn varieties
often were marketed under many names. After 1951, federal regulations required
hybrid seed corn varieties introduced into interstate commerce to use only one varie-
tal name for each variety. See 7 C.F.R. § 201.34(d)(6) (1992).
13. 7 U.S.C. § 1551 (1988).
14. 7 C.F.R. § 201 (1992).
1993]
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ulations make the renaming of a variety previously marketed
under another varietal name illegal.' 5
In the late 1970's, the United States Department of Agricul-
ture (USDA) attempted to police varietal labeling by proposing
what was commonly referred to as a "look-alike" program.'6
When the look-alike program was considered, the relative sig-
nificance of mislabeling incidents in the seed industry-com-
pared to other periods in the history of the industry-was
subject to reasonable and legitimate debate. The program
consisted principally of a visual appraisal to prevent varietal
mislabeling in a number of agronomically significant crops.' 7
The USDA's concern was that a number of the hybrids and
open-pollinated varieties marketed under different varietal
names were in fact the same varieties.' 8 Some varietal misla-
beling continued to occur' 9 and the program ultimately failed,
in part because it was based on "questionable assumptions and
scientific procedures. '"20
2. Transgenic Plants
New techniques in genetic engineering have led to the intro-
duction of transgenic plants. 2' The products of the new tech-
nologies appear to be close to commercialization. Calgene's
FLAVR SAVR( tomato is presently advancing through what
may be the final stages of the Food and Drug Administration
regulatory process. 2 2 Monsanto has entered into an agree-
ment with Delta & Pine Land Company to commercialize its Bt
cotton as the product enters the later stages of the Environ-
15. 7 U.S.C. §§ 1571(a)(1), 1571(d), 1596(a) (1988); 7 C.F.R. §§ 201.10, 201.12,
201.34(d) (2) (1992).
16. See Creech, supra note 11, at 49-52.
17. See Creech, supra note 11, at 49.
18. The use of primarily visual techniques in the evaluation process was vigor-
ously opposed by the seed industry. Many of the major seed companies at the time
argued that there were different strains or races having different physiological char-
acteristics which should be considered different varieties, even though physical ap-
pearances were similar, if not identical. See Creech, supra note 11, at App. H.
19. See, e.g., In Re Stauffer Seeds, Inc., 817 F.2d 47 (8th Cir. 1987) (finding varie-
tal mislabeling in underlying action); Pioneer Hi-Bred Int'l, Inc. v. Holden Found.
Seeds, Inc., No. 81-60-E (S.D. Iowa 1987) (alleging varietal misappropriation).
20. See Creech, supra note 11, at 49. One of the problems with the program was
that plants of the same variety may look different when subjected to different envi-
ronmental circumstances. Likewise, different varieties may look the same. Id.
21. See KLOPPENBURG, supra note 1, at 16.
22. 57 Fed. Reg. 22,772 (1992).
[Vol. 19
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mental Protection Agency regulatory process. 21 While the ulti-
mate commercial impact of these initial products is unknown,
the regulatory process for the introduction of new products is
slowly being developed.
III. INTELLECTUAL PROPERTY RIGHTS PROTECTION
Developments in both animal and plant biotechnology have
created many new issues involving the protection of intellec-
tual property rights. Only recently have both animal and many
previously unprotected forms of plant life been considered
patentable subject matter.24 However, the protection of intel-
lectual property rights in animals and plants has developed
differently.
25
A. Animal Protection
Private breeding efforts with respect to many agriculturally
significant animals have been quite public. Purebred breed as-
sociation registries have been kept for many years. These re-
gistries record ancestral heritage information. In contrast, the
seed and plant industry has developed much differently. Plant
breeding efforts are often done privately, 26 and products and
processes have been protected as trade secrets.
B. Plant Protection
1. Patent Protection of Plants
a. The Plant Patent Act
In 1930, the Plant Patent Act (PPA) was passed to provide
patent protection to asexually reproduced plant varieties.27
23. 56 Fed. Reg. 65,073 (1991).
24. 35 U.S.C. § 101 (1988). See generally Cathy Musco, Could the Patenting of Ani-
mals Lead the Island of Dr. Moreau to Your Backyard?, 8 TEMP. ENVTL. LAw & TECH. J.
119, 121-28 (1989).
25. Potentially patentable animals are likely to be transgenic animals produced
via recombinant DNA techniques or through other applications of genetic engineer-
ing. See O'Connor, supra note 8, at 608. Transgenic animals are created by augmen-
tation of the organism's naturally occurring DNA by addition of additional DNA from
a source other than the parental germplasm. Id. The usual source of the additional
DNA is another animal. Id.
26. While releases by public institutions have been an exception, even public
plant breeding efforts have involved a greater degree of secrecy than has generally
been present with animal breeding. See NicholasJ. Seay, Protecting the Seeds of Innova-
tion: Patenting Plants, 16 AIPLA OJ.. 418, 425-26 (1989).
27. 35 U.S.C. § 161 (1988). Originally passed in 1930, the current version was
1993]
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The legislation, however, was very limited and did not extend
patent coverage to tuber-propagated plants, such as the potato
and the Jerusalem artichoke.2 ' The PPA further required only
that an asexually reproduced plant be new and distinct.2 9
b. The Plant Variety Protection Act
In 1970, the Plant Variety Protection Act (PVPA) extended a
new form of patent-like protection to sexually reproduced
plant varieties. 30  Like the PPA, the protection afforded by
PVPA is limited. PVPA protection does not extend to "fungi,
bacteria, or first generation hybrids. ' ' 3' Unlike the PPA, the
PVPA is administered directly by the USDA. 32
The PVPA uses three criteria to determine the protectability
of novel plant varieties: distinctness, uniformity, and stabil-
ity.33 If a plant variety is considered distinct, uniform, and sta-
ble, the USDA issues a certificate of protection for an eighteen
year period. 34 The certificate of protection grants the breeder
the right to exclude others from selling, reproducing, import-
ing, exporting, or using the protected variety in producing (as
distinguished from developing) a hybrid or different variety. 5
amended in 1954 and provides that discovered plant seedlings are patentable if re-
produced asexually with characteristics distinct from other plants. Id.
28. See generally Seay, supra note 26, at 419-23. The Act was "limited specifically
to plants and plant varieties which [had] already reproduced asexually." Id. at 420.
A subsequent amendment excluded "plants found in an uncultivated state." Id. at
421.
29. 35 U.S.C. § 161 (1988).
30. 7 U.S.C. § 2402 (1988).
31. Id. § 2402(a) (1988). See Seay, supra note 26, at 423-25.
32. 7 U.S.C. § 2321 (1988).
33. Id. § 2401(a). The statute defines these criteria:
(1) Distinctness in the sense that the variety clearly differs by one or
more identifiable morphological, physiological or other characteristics
(which may include those evidenced by processing or product characteris-
tics, for example, milling and baking characteristics in the case of wheat) as
to which a differenec (sic) in genealogy may contribute evidence, from all
prior varieties of public knowledge at the date of determination within the
provisions of section 2402 of this title; and
(2) Uniformity in the sense that any variations are describable, predict-
able and commercially acceptable; and
(3) Stability in the sense that the variety, when sexually reproduced or
reconstituted, will remain unchanged with regard to its essential and distinc-
tive characteristics with a reasonable degree of reliability commensurate
with that of varieties of the same category in which the same breeding
method is employed.
Id.
34. Id. § 2483(b).
35. Id. § 2483(a). In addition, the owner may request that the certificate of pro-
[Vol. 19
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The PVPA includes three exemptions not found in the PPA
or the general utility patent statute:3 6 (1) the crop exemption;
3 7
(2) the research exemption;38 and (3) an intermediary exemp-
tion. 9 The most controversial of the three exemptions-the
crop exemption-has been interpreted to exempt sales from
one farmer directly to another.4" In wheat, for example, the
crop exemption has caused a significant transfer of genetic ma-
terial to farmers who consequently do not need to re-enter the
market to buy new seed each year.
The leading case decided under the PVPA is Delta & Pine
Land Co. v. Peoples Gin Co. ," a case involving the construction of
the crop exemption.42 In Delta & Pine, Peoples Gin asserted
that, as an agricultural cooperative, it acted as a mere agent for
the member farmers' delivery, shipment, and transfer of Delta
& Pine Land Company's protected Deltapine 41 cottonseed.43
Thus, Peoples Gin argued its activities fell within the crop ex-
emption.4 4 The United States District Court for the Northern
District of Mississippi agreed that Peoples Gin was the agent of
its member farmers. 45 However, the court held that the ex-
emption analysis did not end with the agent determination.46
tection specify that in the United States, seed of the variety shall be sold by variety
name only as a class of certified seed and, if specified, shall conform to the number of
generations designated by the owner. Id. See generally Seay, supra note 26, at 424-25.
36. 35 U.S.C. § 101 (1988).
37. 7 U.S.C. § 2543 (1988).
38. Id. § 2544.
39. Id. § 2545.
40. Delta & Pine Land Co. v. Peoples Gin Co., 694 F.2d 1012, 1016 (5th Cir.
1983). The court stated that this interpretation conforms with the Act's purpose
while preserving the farmer's right to sell his seed directly to other farmers. Id. at
1016. A farmer is statutorily defined as "a person whose primary farming occupation
is the growing of crops for sale for other than reproductive purposes." 7 U.S.C.
§ 2543 (1988).
41. 546 F. Supp. 939 (N.D. Miss. 1982).
42. 7 U.S.C. § 2543 (1988). Section 2543 provides in part:
Except to the extent that such action may constitute an infringement
under subsections (3) and (4) of section 2541 of this title, it shall not in-
fringe any right hereunder for a person to save seed produced by him from
seed obtained, or descended from seed obtained, by authority of the owner
of the variety for seeding purposes and use such saved seed in the produc-
tion of a crop for use on his farm, or for sale as provided in this section ....
Id.
43. Delta & Pine Land Co., 546 F. Supp. at 940-41.
44. Id.
45. Id.
46. Delta & Pine Land Co. v. Peoples Gin Co., 546 F. Supp. 939, 943 (N.D. Miss.
1982).
1993]
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In construing the statute and the exemption, the court deter-
mined that if Peoples Gin were to fall within the scope of the
exemption, the declared purposes of the Act would be frus-
trated.47 The court distinguished between direct farmer to
farmer sales and those assisted by the involvement of a third
party.48 The court held that the Act exempted only sales be-
tween farmers "without the intervention and assistance of in-
dependent agents to bring buyer and seller together."'4 9
Peoples Gin was also found in violation of section 2541 of the
Act since its sales were not in compliance with Mississippi's
strict seed labeling requirements. 50 Hollandale Seed & Delint-
ing Company, a co-defendant in the case, was also found to
have violated the Act because the variety was dispensed with-
out notice to the purchasers that the seed was a protected vari-
ety. 5 The Fifth Circuit affirmed the district court's decision.
52
Farmers continue to utilize the crop exemption, and dis-
putes often arise over the exemption's applicability. 53 The dis-
pute over the statutory crop exemption recently focused on the
number of bushels a farmer could save and sell. In Asgrow Seed
Co. v. Winterboer,54 the Federal Circuit Court of Appeals held
that the crop exemption did not impose a seed quantity unit
upon the selling farmer.55 The holding reversed the district
court's interpretation which had imposed a quantity limitation
on the farmer based on an extension of the policy arguments
set forth in Delta & Pine Land Co..56 The Federal Circuit recog-
nized that the crop exemption could extinguish the incentives
of the PVPA.57 Absent a quantity limitation, the court identi-
47. Id.
48. Id.
49. Id. at 942. See also 7 U.S.C. § 2543 (1988).
50. Delta & Pine Land Co. v. Peoples Gin, Co., 546 F. Supp. 939, 944 (N.D. Miss.
1982).
51. Id. Hollandale provided services for delinting, treating, and bagging the
seed. Id. at 942.
52. Delta & Pine Land Co. v. Peoples Gin Co., 694 F.2d 1012, 1017 (5th Cir.
1983).
53. See Seay, supra note 26, at 425.
54. 982 F.2d 486 (Fed. Cir. 1992).
55. Id. at 491.
56. Asgrow Seed Co. v. Winterboer, 795 F. Supp. 915, 920 (N.D. Iowa 1991).
The district court decided that a farmer whose "primary farming occupation" was the
"growing of crops for sale for other than reproductive purposes" had a limited ex-
emption which entitled the farmer to save or sell only the number of bushels of soy-
beans required to plant that farmer's own acreage in a single year. Id. at 917-18.
57. Asgrow Seed Co., 982 F.2d at 489, 491.
[Vol. 19
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fled a number of other statutory requirements that still must be
met for a farmer to take advantage of the crop exemption.5
The court nevertheless felt compelled to rely on the statute's
wording in determining that the Winterboers did not have a
bushel restriction.
59
Other areas of dispute arising under the PVPA relate to is-
sues such as the availability of the Act's protection and com-
peting rights to a protected variety. 60 However, most of the
disputes to date have centered on the crop exemption.6'
c. The Jones Patent
Disputes over patent rights and patent validity are not new
in the seed industry. The first economically significant patent
to affect the seed industry was the Jones patent, issued by the
Patent Office in 1956.62 The patent claimed a method of hy-
brid seed corn production that utilized genetic factors capable
of restoring pollen fertility to the progeny of cytoplasmic pol-
len sterile strains. 63 The CMS/restorer system, the subject of
the Jones Patent, incorporated cytoplasmic male sterility into
the seed parent and restorer genes into the pollinator.64 The
58. The court's analysis of the crop exemption defined seven express limitations
that restricted a farmer's right to sell seed. The limitations are:
1) A farmer remains subject to infringement under § 2341(3)-(4);
2) A farmer may only save, use, or sell seed produced from or descended
from seed obtained by authority of the PVPA certificate owner for seeding
purposes;
3) A farmer selling a novel variety must primarily grow crops from that seed
for consumption;
4) A farmer acquiring a novel variety must primarily grow crops from that
seed for consumption;
5) A farmer who acquires a novel variety in a brown bag sale can neither
save nor sell seed harvested from that seed;
6) The sale must comply with state laws; and,
7) A farmer cannot divert seed originally sold for consumption to planting
purposes.
Asgrow Seed Co. v. Winterboer, 982 F.2d 486, 490 (Fed. Cir. 1992).
59. Id. at491.
60. For consideration of other cases decided under the PVPA, see Public Vari-
eties, Inc. v. Sun Valley Seed Co., 734 F. Supp. 250 (N.D. Miss. 1990) (holding that
licensee lacked standing to bring action for alleged infringement); Heart Seed Co. v.
Seeds, Inc., 4 U.S.P.Q2d (BNA) 1324 (E.D. Wash. 1987) (enjoining defendant from
further patent infringement); Bud Antle, Inc. v. Scattini Seed Co., 229 U.S.P.Q2d
(BNA) 547 (N.D. Cal. 1985) (holding that defendant can sell seed only on the condi-
tion that defendant not propagate the seed).
61. See Seay, supra note 26, at 425.
62. Jones Patent 2,753,663 (entitled Production of Hybrid Seed Corn).
63. See generally KLOPPENBURG, supra note 1, at 113-16.
64. Id.
19931
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application of the system had significant economic effect by
eliminating the need for detasselling crews in hybrid seed corn
production fields.65 The resulting reduction of labor costs
lowered the cost of hybrid seed corn production and allowed
for higher profit margins.66 By the mid-1960's much of the hy-
brid seed corn sold in the United States had incorporated the
67CMS/restorer process.
Although the seed industry was using the CMS/restorer pro-
cess, Research Corporation, the assignee of the patent by
Jones, was unable to convince the industry to honor the patent
and pay royalties. In 1963, Research Corporation filed suit in
federal district court in Chicago to enforce its patent.68 After
litigating for a number of years, the parties eventually settled
but only after extensive discovery had been taken and after Re-
search Corporation had filed a class action antitrust suit
against all of the companies in the seed industry who utilized
the patent.69
Ironically, the patent litigation may have been responsible,
at least in part, for the quick rebound the hybrid seed corn
industry made after the Southern Corn Leaf Blight of 1970-
1971.70 On December 3, 1968, Research Corporation filed an-
65. See Marc Linder, Crewleaders and Agricultural Sweatshops: The Lawful and Unlawful
Exploitations of Migrant Farmworkers, 23 CREIGHTON L. REV. 213, 215 (1989). Histori-
cally, seed companies employed local teens, college students, and migrant workers as
their labor force. Id. at 215. The introduction of cytoplasmic male sterility elimi-
nated the need for manual detasseling. Id. at 215 n. 15.
66. See William L. Brown, Hybrid Vim and Vigor: George Shull's Experiments With In-
breeding and Crossbreeding Corn, 5 Sci., Nov. 1984, at 77 (noting that adoption of hybrid
corn also added a value of several billion dollars per year to the farmer over the
period of 1930-1979).
67. See KLOPPENBURG, supra note 1, at 113.
68. See Research Corp. v. Pfister Assoc'd Growers, Inc., 310 F. Supp. 1377 (N.D.
Ill. 1970).
69. See Research Corp. v. Asgrow Seed Co., 425 F.2d 1059 (7th Cir. 1970).
While under advisement, the case was consolidated with another infringement action
on the same patent. Id. at 1059. The consolidation later resulted in class action
certification. Research Corp. v. Pfister Assoc'd Growers, Inc., 301 F. Supp. 497, 498
(N.D. Ill. 1969) (certifying the case as a class action). On January 22, 1970, the Sev-
enth Circuit Court of Appeals dismissed an appeal of a consent judgment. Asgrow,
425 F.2d at 1059 (dismissing appeal on grounds defendants failed to adequately ob-
ject to the settlement).
70. An interesting aspect of the Research Corporation litigation is that much of
the germplasm being used in the industry was T-cytoplasm material. See generally
KLOPPENBURG, supra note 1. This material was later discovered to be susceptible to
the Southern Corn Leaf Blight which decimated the corn crops in much of the Mid-
western corn belt in 1970 and, to a lesser extent, in 1971. See Lucas v. Pioneer, Inc.,
[Vol. 19
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other suit. 7 ' Funk Brothers was charged with returning to
other parent lines and refusing to pay royalties despite a nego-
tiated licensing agreement between Funk Brothers and Re-
search Corporation for the Jones patent. Research
Corporation alleged that Funk Brothers intended to switch
parent lines before the settlement was entered and falsely rep-
resented in the licensing negotiations that Funk Brothers in-
tended to continue use of the CMS/restorer process.72
d. The General Utility Patent Statute
Increasingly, the Patent and Trademark Office (PTO) has is-
sued patents for hybrids, seeds, plants, plant parts, and parent
inbreds. However, animal patents are still somewhat slow to
issue.7" While the celebrated Harvard Mouse patent was
granted in April 1988, 74 almost five years passed without the
issuance of another transgenic animal patent. The drought re-
cently ended. On December 29, 1992, the PTO issued three
new patents for genetically engineered mice.75
In 1980, the United States Supreme Court determined that a
live, human-made microorganism was patentable subject mat-
ter under the general utility patent statute.76 In Diamond v.
Chakrabarty77 the Court held that the living or nonliving char-
acter of an invention has no bearing on patentability.78
256 N.W.2d 167, 171 (Iowa 1977) (farmers brought class action suits against seed
companies in reaction to the corn blight). See also JACK DOYLE, ALTERED HARVEST:
AGRICULTURE, GENETICS, AND THE FATE OF THE WORLD'S FOOD SUPPLY 1-15 (1985).
As a result of the Jones patent litigation, some in the seed industry, such as Funk
Bros., may have decided to switch to germplasm resistant to the Southern Corn Leaf
Blight before the disease compelled the change.
71. See Complaint, Research Corp. v. Funk Bros. Seed Co., No. 68 C 2336 (N.D.
I11. Dec. 3, 1968) (on file with the William Mitchell Law Review).
72. Complaint at 7-8, Research Corp. v. Funk Bros. Seed Co., No. 68 C 2336
(N.D. Ill. Dec. 3, 1968) (on file with the William Mitchell Law Review).
73. See generally Czarnetzky, supra note 5; O'Connor, supra note 8; Musco, supra
note 24.
74. Leder et al. Patent 4,736,866 (entitled Transgenic Non-Human Animals)
[hereinafter Harvard Mouse]. See Czarnetzky, supra note 5, at 1356-57.
75. 45 PAT. TRADEMARK & COPYRIGHTJ. (BNA) 159 (1993) (describing the first
animal patents issued since the Harvard Mouse patent). But see 45 PAT. TRADEMARK &
COPYRIGHT J. (BNA) 347, 354 (1993). Senator Mark Hatfield has proposed a two-
year moratorium for animal and gene patents, a proposal prompted in part by the
three mouse patents issued by the PTO in December 1992. Id.
76. 447 U.S. 303 (1980).
77. Id. at 309-10. The general utility patent statute is located at 35 U.S.C. § 101
(1988).
78. Chakrabarty, 447 U.S. at 313.
1993]
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Rather, the important distinction is whether the product was
derived from human effort and meets the criteria of novelty,
utility, and non-obviousness.79
The Chakrabarty decision first opened the door to the possi-
bility of protection for both plant and animal life under the
general utility patent statute. 0 While the decision reiterated
the statutory requirements of utility and newness, Chakrabarty
removed the restrictive subject matter limitations created by
the PPA and the PVPA.8 '
Following Chakrabarty, the Court's interpretation of the gen-
eral utility patent statute's relationship to the PPA and the
PVPA was considered, by some, to be unclear. Finally, the is-
sue was specifically addressed in 1985. In Ex parte Hibberd,82
the PTO stated that the plant-specific statutes were not restric-
tions on the general utility patent statute and were not the ex-
clusive forms of protection for plant life.8 3 Two years later, in
Ex Parte Allen,84 the PTO further stated that the general utility
patent statute's scope "clearly indicates man-made life
forms."85
Shortly after Ex parte Allen was decided, the PTO published a
notice in the Official Gazette stating that "nonnaturally occurring
nonhuman multicellular living organisms, including animals,
constituted patentable subject matter" within the scope of the
general utility patent statute.8 6 This announcement ultimately
sparked the filing of a lawsuit by a group of individual farmers,
animal husbanders and non-profit corporations.
In Animal Legal Defense Fund v. Quigg,8 7 the plaintiffs alleged
that the PTO violated the Administrative Procedures Act8 8 by
failing to provide for public notice and comments before issu-
ing the notice.8 9 The plaintiffs also alleged that the notice ex-
79. Id.
80. Diamond v. Chakrabarty, 447 U.S. 303, 313 (1980).
81. In order to apply the general utility patent statute to human-made orga-
nisms, the Court offered a broad interpretation of the language of the statute.
Chakrabarty, 447 U.S. at 310.
82. 227 U.S.P.Q. (BNA) 443 (Bd. Pat. App. & Interferences 1985).
83. Id.
84. 2 U.S.P.Q. (BNA) 1425 (Bd. Pat. App. & Interferences 1987).
85. Id. at 1427.
86. 1077 Off. Gaz. Pat. Office 24 (April 21, 1987).
87. 710 F. Supp. 728 (N.D. Cal. 1989).
88. 5 U.S.C. §§ 551-59 (1988).
89. Animal Legal Defense Fund, 710 F. Supp. at 729-31.
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ceeded the PTO's statutory authority. 90 The court disagreed,
holding that the notice was interpretative of earlier PTO ad-
ministrative decisions and court decisions and "thereby ex-
empt from the public notice and comments requirement of the
APA." 9 1 The court further commented that "because the PTO
is authorized to issue [interpretative] rules" and because the
notice "neither abridge[d] nor enlarge[d] the rights of anyone,
the PTO could not ... have exceeded its statutory authority in
promulgating [the notice]. 92 The Court of Appeals for the
Federal Circuit affirmed,93 finding that, because the rule was
deemed to be interpretive rather than substantive, public no-
tice or comment was not required prior to promulgation.94
Other noteworthy cases concerning seed or animal products
patented under the general utility patent statute have not yet
materialized. However, some suits are beginning to emerge.
In Florida, a patent suit for a tomato with long shelf life
properties 95 is currently pending.96 Another dispute that ulti-
mately may prove significant is the interference proceeding
which ICI Americas has instituted in the Patent Office to chal-
lenge Calgene's antisense patent.97
2. Trade Secret Protection of Plants
Pioneer Hi-Bred International, Inc. v. Holden Foundation Seeds,
Inc.98 is perhaps the most significant case involving the asser-
tion of a trade secret theory. Pioneer's principal allegation was
that Holden had misappropriated several of Pioneer's inbred
lines. 99 The key parent line Pioneer appeared to be concerned
about was the line designated "H3H." 00 Pioneer did not have
90. Id. at 729.
91. Id. at 732.
92. Animal Legal Defense Fund v. Quigg, 710 F. Supp. 728, 732 (N.D. Cal.
1989).
93. Animal Legal Defense Fund v. Quigg, 932 F.2d 920 (Fed. Cir. 1991).
94. Id. at 931.
95. Nahum Patent 4,843,186 (entitled Long Shelf Life Heterozygous Tomato
Plant).
96. Agricultural Seed Technologies, Inc. v. LSL Biotechnologies, No. 91-572-
CIV-ORL-19 (M.D. Fla. 1991) (on file with the William Mitchell Law Review).
97. Hiatt et al. Patent No. 4,801,540 (entitled PG Gene and its Use in Plants).
ICI Challenges Calgene Plant Antisense Patent, GENETIC TECH. NEWS, Aug. 1992, at 6, 6.
98. No. 81-60-E (S.D. Iowa Oct. 29, 1987) (Findings of Fact, Conclusions of Law
and Decrees) (on file with the William Mitchell Law Review).
99. Id. at 11.
100. Id. at 16.
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PVPA protection or any other form of patent type protection
for H3H. l0 ' While no direct evidence demonstrated that
Holden had misappropriated the line, the court observed that
Holden had previously isolated Pioneer parent lines in seed
production fields.' 0 2 Based on that evidence and on conclu-
sions that the court drew from the results of a series of electro-
phoresis and chromatography tests conducted during the
litigation, the court concluded that Holden had, in fact, ob-
tained Pioneer's H3H parent line through improper means.l°0
Because no Plant Variety Protection or any other form of pat-
ent-type protection existed on Pioneer's parent inbreds, Pio-
neer asserted Lanham Act, trade secret, conversion,
interference with business advantage, unjust enrichment, and
unfair competition theories.' 04 The court found for Pioneer
on all claims but one.10 5 The court ruled for Holden on the
unfair competition theory.
0 6
In finding Pioneer's trade secrets theory applicable, the
court held that the "genetic messages" of Pioneer's parent in-
breds were trade secrets.' 0 7 The court acknowledged that the
usual requirement under Iowa law-that the acquisition of a
trade secret must be "as a result of a confidential relation-
ship"-was not met but held that the tort of misappropriation
of trade secrets could also focus on whether the secret was dis-
covered by "improper means."'0 8 The court concluded that
Pioneer had met its burden of showing misappropriation 9
and ruled that the burden shifted to Holden to show that
either Pioneer's inbred lines were lawfully acquired or
Holden's inbred lines "LH38," "LH39," and "LH40" were de-
101. Id. at 29.
102. Id. at 107.
103. Pioneer Hi-Bred Int'l, Inc. v. Holden Found. Seeds, Inc., No. 81-60-E, at 54
(S.D. Iowa Oct. 29, 1987) (Findings of Fact, Conclusions of Law and Decrees) (on file
with the William Mitchell Law Review).
104. Id. at 2.
105. Pioneer prevailed on the Lanham Act, trade secret, conversion, interference
with business advantage, and unjust enrichment theories. Id.
106. Pioneer Hi-Bred Int'l, Inc. v. Holden Found. Seeds, Inc., No. 81-60-E, at
106-07 (S.D. Iowa Oct. 29, 1987) (Findings of Fact, Conclusions of Law and Decrees)
(on file with the William Mitchell Law Review).
107. Id. at 72. The genetic messages of H3H and H435Z7 did not exist outside of
Pioneer's fields and the fields of its contractors. Evidence revealed that Pioneer has
taken reasonable precautions to protect the secrecy of the genetics. Id.
108. Id. at 72-73.
109. Id. at 74.
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veloped independently of Pioneer's "H3H" and/or "H43SZ7"
lines. ' 10 The court concluded that Holden had not met this
burden. I"
On December 30, 1991, following a trial on the damage is-
sue, the district court entered a judgment in favor of Pioneer in
the amount of $46,703,230.112 Postjudgment motions are still
pending, and appeals may ultimately be taken.'
1 3
The Board of Trustees of the University of Illinois v. Pioneer Hi-Bred
International, Inc., 114 involved a suit filed by the University of
Illinois, DuPont, and Pfister against Pioneer, under the Illinois
Trade Secrets Act and other theories.' 15 The University of Illi-
nois had entered into an exclusive licensing agreement with
DuPont and Pfister under which the University granted to Du-
pont and Pfister the exclusive right to commercialize five high
oil corn lines developed by the University." t 6 Pioneer initially
expressed interest in bidding for the exclusive license but later
withdrew from the bidding process.'' 7 Pioneer continued to
express interest in receiving the high oil lines and ultimately
requested them from the University's Dr. Alexander."' Dr.
Alexander agreed to send Pioneer three lines that had already
been released by the Illinois Agricultural Experiment Sta-
tion." 9 When the seed was forwarded to Pioneer, the three
released lines were present.120 However, five seed populations
that were the subject of the upcoming exclusive license were
also provided.' 21 The University asserted that the release was
a mistake and alleged that Alexander's authority to release the
seed populations to third parties was restricted.
22
110. Pioneer Hi-Bred Int'l, Inc. v. Holden Found. Seeds, Inc., No. 81-60-E at 75
(S.D. Iowa Oct. 29, 1987) (Findings of Fact, Conclusions of Law and Decrees) (on file
with the William Mitchell Law Review).
111. Id.
112. See Seed Firm to Appeal Judgment, CHI. TRIB., January 1, 1992 at C3.
113. Id.
114. Board of Trustees v. Pioneer Hi-Bred Int'l, Inc., No. 90-2038 (C.D. Ill. Jan.
31, 1990) (Complaint) (on file with William Mitchell Law Review).
115. Id.
116. Id. at 11.
117. Id.
118. Id.
119. Board of Trustees v. Pioneer Hi-Bred Int'l, Inc., No. 90-2038 at 10 (C.D. Ill.
Jan. 31, 1990) (Complaint) (on file with William Mitchell Law Review).
120. Id.
121. Id.
122. Id. at 12.
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On a motion for preliminary injunction, the court prohibited
Pioneer from using, developing or distributing any of the high-
oil seed or its progeny during the pendency of the litigation.
23
After an appeal from the injunction order was filed, the case
was settled.
3. Product Liability Ramifications of Patent Protection
Transgenic plant patents have potential product liability
ramifications. Thus, civil courts may ultimately play a signifi-
cant role in regulation of the products of biotechnology.' 2 4
While the scope of the civil courts' role is largely undeter-
mined at the present time, disputes regarding products liability
are almost certain to arise.
Product liability disputes may potentially arise where compa-
nies target their research efforts to develop insect and disease
resistant plants. To the extent that research efforts success-
fully result in the issuance of either plant variety protection
certificates or utility patents with claims directed to disease or
insect resistant features, the companies developing the prod-
ucts will need to rigorously test their products before making
any specific claims.
When a product is patented, the patentee receives a statu-
tory right to exclude others from making, using or selling the
patented product in return for public disclosure of the best
mode of his or her invention.' 25 Because the product is re-
quired to be capable of a written description, 26 an inventor
necessarily sets forth statements that "describe" the invention
in the application process. 27 After the patent issues, these
statements become a matter of public record. Thus, if a trans-
genic plant is claimed to be resistant to a particular viral dis-
ease and a patent is issued for the product, a sale of the
patented product would likely be accompanied with the de-
scription of the qualities and disease resistance features of the
123. Board of Trustees v. Pioneer Hi-Bred Int'l, Inc., No. 90-2038 (C.D. Ill. May
18, 1990) (Order on Plaintiff's Motion for a Preliminary Injunction) (on file with the
William Mitchell Law Review).
124. For a discussion of future regulations, see infra Part.V.
125. 35 U.S.C. § 154 (1988).
126. Id. § 112.
127. Id. The statements include a written description of the invention as well as
the manner and process of making and using the invention. Id.
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plant as disclosed in the patent application. 28
While disease "resistance" and disease "tolerance" are not
new terms, these terms may take on a new meaning when used
in connection with transgenic patented plants. The public may
have exceedingly high expectations regarding the capabilities
of the transgenic product.129 Should these products fail to live
up to their promised billing, grower suits can be expected.
3 0
If suits result, virtually unprecedented attention may be di-
rected toward the validity of the underlying tests and research
that support the data disclosed in the publicly filed patent
applications.
At the time of the Southern Corn Leaf Blight in 1970 and
1971, major class action litigation was filed against the compa-
nies using the T-cytoplasm germplasm.' 3' The only patent in
existence at that time that might potentially have become in-
volved in the litigation (it did not) was the Jones process patent
on the CMS/restorer process of hybrid development. The
Jones patent was only a process patent, not a product patent;
the Jones patent did not contain any claims directed to disease
resistance features. There were no publicly disclosed-and no
publicly available-representations with respect to disease
resistance to be found in any product patent filings. If product
patents claiming disease or insect resistant features had ex-
isted, however, the litigation may have been somewhat more
difficult for the seed companies to defend and may have re-
quired the utilization of other defenses.
Even if internally prepared scientific testing procedures are
strictly followed, liability exposure can still be significant. This
is best illustrated by a recent decision involving an onion hy-
brid. 3 2 In Lutz Farms v. Asgrow Seed Co.,13 the Tenth Circuit
affirmed a judgment of $2,931,254.96 against Asgrow arising
128. See, e.g., U.C.C. § 2-313(1)(b) (1992). "Any description of the goods which is
made part of the basis of the bargain creates an express warranty that the goods shall
conform to the description." Id.
129. Already, the term "resistant" has been used to describe some of the products
of biotechnology. See Notices, 57 Fed. Reg. 24,235-37 (1992).
130. See, e.g., Lucas v. Pioneer, Inc., 256 N.W.2d 167 (Iowa 1977).
131. See id.
132. Lutz Farms v. Asgrow Seed Co., 948 F.2d 638 (10th Cir. 1991). A group of
farmers brought suit against a seed seller for damages caused by the genetic defects
in onion seeds that produced "double and misshapen onions." Id. at 640.
133. Id. at 638.
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out of a case of unsalable double onions. 134 The court stressed
the fact that Asgrow emphasized its genetic testing and quality
control programs in its marketing efforts.' 35 The court also
noted that, in violation of its own internal procedures, Asgrow
failed to test the pollinator seed parent of the seed sold to the
Lutz Farms. '
3 6
As more plants are genetically modified to include resistance
to particular insects, diseases, or herbicides, it can be reason-
ably anticipated that rigorous statistical testing will be required
before the products are introduced into the marketplace.
Whether government agencies, acting as independent third
parties, will play a significant role in such testing will largely
depend upon how the products are developed and promoted.
IV. PRODUCT TESTING AND INTRODUCTION
Congress has not enacted specific legislation to govern the
products of biotechnology. 137 In its absence, products are be-
ing federally regulated by three separate agencies: the Animal
and Plant Health Inspection Service of the United States De-
partment of Agriculture, the Environmental Protection
Agency, and the Food and Drug Administration.
A. The United States Department of Agriculture
The USDA's Animal and Plant Health Inspection Service
(APHIS) considers the source of its regulatory authority to be
the Plant Quarantine Act of 1912,138 the Federal Plant Pest Act
of 1957 39 and the Federal Noxious Weed Act.' 4 ° APHIS pub-
lished regulations on June 16, 1987,14' setting forth its field
134. Of the total amount, $1.2 million was allocated for pure economic loss. An
additional $800,000 was assessed for punitive damages and another $425,000 for
emotional distress damages. Id. at 639.
135. Id. at 640 n.l.
136. Id. at 647.
137. Although some bills to address genetically altered animal issues have been
introduced into Congress, none have become law. O'Connor, supra note 8 (an over-
view of recent congressional action on genetically altered animals). See also
Czarnetzky, supra note 5 (advocating the need for Congress to adopt patent laws to
protect genetically engineered animals).
138. 7 U.S.C. § 151 (1988).
139. 7 U.S.C. §§ 150(aa)-(jj) (1988 & Supp. III 1991).
140. 7 U.S.C. § 2801 (1988).
141. 7 C.F.R. § 340 (1992).
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testing permit procedure. 42  The APHIS procedure requires
companies seeking to release any regulated article 4 ' into the
environment to obtain a permit from APHIS prior to its
release. 1
44
The permit application is to be submitted at least 120 days in
advance of the proposed release. 145 An initial review will be
completed within thirty days of receipt of the application to
determine whether the application was completed correctly. 1
46
The applicant will then be notified that the APHIS 120 day re-
view period has begun to run.
47
Prior to the expiration of the review period, the applicant
will be informed whether approval has been granted or de-
nied. 48  At a minimum, a granted permit is subject to the ten
conditions set forth in the regulations. 49 If the permit is de-
nied, the regulations provide for an appeal procedure. 15 0
142. Id. § 340.3 (1992).
143. Id. § 340 (1992). The term "regulated article" is defined as follows:
Regulated Article. Any organism which has been altered or produced through
genetic engineering, if the donor organism, recipient organism, or vector or
vector agent belongs to any genera or taxa designated in § 340.2 of this part
and meets the definition of plant pest, or is an unclassified organism and/or
an organism whose classification is unknown, or any product which contains
such as [sic] organism, or any other organism or product altered or pro-
duced through genetic engineering which the Deputy Administrator deter-
mines is a plant pest or has reason to believe is a plant pest. Excluded are
recipient microorganisms which are not plant pests and which have resulted
from the addition of genetic material from a donor organism where the ma-
terial is well characterized and contains only non-coding regulatory regions.
Id.
144. Id.
145. 7 C.F.R. § 340.3(b) (1992).
146. Id.
147. Id.
148. Id. § 340.3(e) (1992).
149. Id. § 340.3(0 (1992). Briefly, the ten conditions are
1. Proper maintenance and disposition.
2. Proper disposal and shipping material.
3. Separation from other organisms.
4. Confinement to specified areas.
5. Access to inspection.
6. Proper identification.
7. Prevention of accidental or unauthorized release.
8. Prevention of the spread of the plant pests.
9. Monitoring reports.
10. Notification in the event of:
(i) Accidental or unauthorized release.
(ii) Substantially different "characteristics" or "any unusual
occurrence."
Id.
150. Id. § 340.4(g) (1992). The appeal must be submitted within 10 days after
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Once a finding is made that no significant environmental im-
pact will occur if the genetically engineered organism is tested
in the field,' a notice is published in the Federal Register. 152
The APHIS regulations list plant pests and exempted orga-
nisms. 153 A procedure is created under which a petition may
be submitted to amend the list of organisms in Section 340.2
... by adding or deleting any genus, species, or subspecies."' 54
The USDA publishes proposals to amend the APHIS regula-
tions in the Federal Register and solicits comments from the
public.' 55 The Deputy Administrator issues a decision within
180 days of receipt of the petition to amend. 56
On June 2, 1992, APHIS received a request from Calgene,
Inc. for abatement of future regulation of the FLAVR SAVR
tomato as a plant pest or as a "regulated article"' 5 7 on the
ground that the vectors used in producing the tomato were
disarmed. 5 8 APHIS has indicated that, based on the reviews
of a number of field tests of the FLAVR SAVRE tomato and
the information submitted by Calgene in its petition, APHIS
believes that the tomato is not a plant pest and there is no rea-
son to believe that it may otherwise present risk to nontargeted
plants. 59 Thus, APHIS has indicated that the FLAVR SAVRE
tomato is not a regulated article under the APHIS
regulations. 1
60
notification of denial and must "state all of the facts and reasons" why the applicant
believes the decision should be changed. Id.
151. APHIS does not describe what a "significant impact" entails. Rather, APHIS
requires that an organism does not "present a risk of introducing or disseminating a
plant pest and will not have a significant impact on the quality of the human environ-
ment." Notices, 57 Fed. Reg. 24,235 (1992).
152. See, e.g., Notices, 57 Fed. Reg. 24,235-37 (1992).
153. 7 C.F.R. § 340.2 (1992).
154. Id. § 340.4(a).
155. Id. § 340.4(c)(2).
156. Id. § 340.4(c)(3). The petition will either be approved in whole or in part or
denied in whole or in part. Id.
157. Regulation of the FLAVOR SAVR1 was promulgated under 7 C.F.R. § 34
(1992).
158. Notices, 57 Fed. Reg. 31,170 (1992). "Vector" describes the actions of small
DNA rings, or plasmids, capable of replication. As plasmids can pass from one cell to
another, they may be induced to act as vectors, or carriers, of the specified DNA
material. See Czarnetzky, supra note 5, at 1332.
159. Notices, 57 Fed. Reg. 31,170 (1992).
160. Id.
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B. The Environmental Protection Agency
The Environmental Protection Agency (EPA) considers the
source of its authority for regulation of biotechnology prod-
ucts to be the Federal Insecticide, Fungicide and Rodenticide
Act (FIFRA) 6 l  and the Toxic Substances Control Act
(TSCA).' 6 2 FIFRA authorizes the EPA to restrict pesticides
that present "unreasonable adverse" risks to the environ-
ment. 16 3 TSCA allows the EPA to prevent the manufacture or
use of dangerous "chemical substances" not otherwise regu-
lated if lack of prevention would present an "unreasonable risk
of injury to health or the environment."' 64
On December 13, 1991, the EPA published notice that it had
received its first application for an Experimental Use Permit
for a transgenic plant pesticide. 6 5 The request, made by Mon-
santo, was for tests on several forms of the insect control pro-
tein delta-endotoxin 6 6 to be introduced into cotton. 67 Upon
receipt of the request, the EPA solicited public comments con-
cerning Monsanto's application.1
68
On April 10, 1992, after concluding that there was no fore-
161. 7 U.S.C. § 136(c) (1988).
162. 15 U.S.C. § 2601 (1988).
163. 7 U.S.C. § 136(a) (1988). "Unreasonable adverse" risks are defined as "any
unreasonable risk to man or the environment, taking into account the economic, so-
cial, and environmental costs and benefits of the use of any pesticide." Id. § 136(bb).
164. 15 U.S.C. § 2605(a) (1988). A "chemical substance" is defined as "any or-
ganic or inorganic substance of a particular molecular identity, including:
i) any combination of such substances occurring in whole or in part as a
result of a chemical reaction or occurring in nature and
ii) any element or uncombined radical ....
Id.
165. Notice, 56 Fed. Reg. 65,073 (1992). An experimental use permit will be is-
sued only if the EPA determines that the applicant needs more data before a determi-
nation may be made about registration of a pesticide. 7 U.S.C. § 136(c) (1988). A
pesticide must be registered by the EPA before sale or distribution. Id. § 136(a).
166. Delta-endotoxin is an insect control protein derived from a soil microbe. 56
Fed. Reg. 65,073 (1992).
167. Monsanto proposed to transfer the delta-endotoxin gene to cottonseed to
produce a pesticide. 56 Fed. Reg. 65,073 (1992). The proposed testing of these
genetically altered plants would include the following five experiments, designed to
evaluate the performance of the expressed proteins against the pests:
(1) economic threshold;
(2) host plant resistance;
(3) gene evaluations;
(4) population dynamics studies;
(5) threshold treatment determinations.
Id. In addition, breeding nursery and seed increase trials were to be conducted. Id.
168. 56 Fed. Reg. 65,073 (1992). The EPA determined that Monsanto's applica-
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seeable significant risk to humans or to nontarget organisms
from Monsanto's proposed field tests, the EPA issued an Ex-
perimental Use Permit.'6 9 The EPA indicated that the assess-
ment was based solely on Monsanto's application for the
permit.' 70 The EPA again solicited comments from the public
concerning the Monsanto application, stating that "eventual
commercialization of Monsanto's transgenic cotton pesticide
may raise other issues not addressed with this [Environmental
Use Permit].''
C. The Food and Drug Administration
The Food and Drug Administration (FDA) considers the
source of its regulatory authority to be the Federal Food, Drug
and Cosmetic Act (Act).' 72 The FDA's interpretation of the
Act treats all food products alike, whether the products result
from traditional plant breeding methods, recombinant DNA
17
or other genetic engineering techniques.
74
In May 1992, the FDA published notice of receipt of the first
request for consultation concerning a new plant variety devel-
oped through recombinant DNA techniques. 75 The request
concerned Calgene Inc.'s FLAVR SAVR( tomato-a product
claimed to exhibit improved fruit ripening and long shelf life
tion may have been of regional and national significance, therefore, public solicita-
tion of comments was mandatory in accordance with 40 C.F.R. § 172.11 (a). Id.
169. 57 Fed. Reg. 21,655 (1992).
170. Id. The agency's decision was specifically based on the expectation that off-
site movement of the expressed proteins would be minimal because of the limited
acreage utilized and short duration of the field test. Id.
171. 57 Fed. Reg. 21,655 (1992).
172. 21 U.S.C. § 321(b) (1989). In addition,
The Federal Food, Drug and Cosmetic Act (the act) provides the FDA
with broad authority to ensure the safety and wholesomeness of food, em-
powering the agency to initiate legal action against a food that is found to be
adulterated or misbranded within the meaning of the act. Consequently,
firms frequently consult with the agency concerning potential safety and
regulatory issues that may be associated with food products developed
through new technology. FDA believes that such consultations are impor-
tant for the agency to be knowledgeable about current methods of food pro-
duction and to carry out its responsibility to protect public health.
57 Fed. Reg. 22,772 (1992).
173. Recombinant DNA results from the insertion into a DNA chain, through
chemical or biological means, of a sequence not originally present in that chain.
STEDMAN'S MEDICAL DICTIONARY 1331 (25th ed. 1990).
174. 57 Fed. Reg. 22,984 (1992).
175. Calgene's request was published separately at 57 Fed. Reg. 22,772 (1992)
with a comment period that remained open through July 28, 1992. 57 Fed. Reg.
22,772 (1992).
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properties. 7 6 Upon receipt of Calgene's request, the FDA
solicited public comment on the request.
177
V. FUTURE REGULATION
The future of biotechnology regulation is uncertain. In Feb-
ruary 1991, the President's Council on Competitiveness issued
a report regarding the continued deregulation of biotechnol-
ogy.' 78 This report recommended four principles to shape the
development and streamlining of biotechnology regulation. 
79
These principles were developed in an attempt to produce reg-
ulatory uniformity among the FDA, EPA and USDA.' 80 The
report of the Council on Competitiveness attempted to focus
the scope of the agencies' oversight on "risk-based" regulation
rather than "turf-based regulation."'
On May 26, 1992, Health and Human Services Secretary
176. 57 Fed. Reg. 22,772 (1992). Specifically, Calgene asked for an advisory opin-
ion concerning whether FLAVR SAVR( tomatoes are food and, therefore, subject to
the same regulation as other tomato varieties. Id.
177. 57 Fed. Reg. 22,772 (1992). Subsequently, Calgene has also asked the FDA
to review the Kanamycin-resistance marker gene and its protein (utilized in produc-
ing the FLAVR SAVR( tomato) under the FDA's food additive regulations. Calgene
Seeks FDA Approval of Marker Gene Used in Tomatoes, FOOD CHEMICAL NEWS, January 11,
1993.
178. PRESIDENT'S COUNCIL ON COMPETITIVENESS, REPORT ON NATIONAL BIOTECH-
NOLOGY POLICY (1991).
179. The four principles are:
1. Federal government regulatory oversight should focus on the character-
istics and risks of the biotechnology product - not the process by which it is
created....
2. For biotechnology products that require review, regulatory review
should be designed to minimize regulatory burden while assuring protec-
tion of public health and welfare....
3. Regulatory programs should be designed to accommodate the rapid ad-
vances in biotechnology. Performance - based standards are, therefore,
generally preferred over design standards. ...
4. In order to create opportunities for the application of innovative new
biotechnology products, all regulation in environmental and health areas -
whether or not they address Biotechnology - should use performance stan-
dards rather than specifying rigid controls or specific designs for
compliance.
Id. at 12-13.
180. Prior to the Council's report, the FDA had announced that it did not need to
establish further regulatory procedures or requirements to review new biotechnology
products. On the other hand, the EPA and the USDA had announced plans to de-
velop further rules and guidelines for reviewing the products. Id. at 12.
181. Id.
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Louis W. Sullivan announced a new policy stating that the FDA
will regulate new varieties of whole foods developed through
biotechnology by applying the same standards as those used in
"traditional foods."' 18 2 The FDA's policy describes the scien-
tific basis for evaluating and ensuring the safety of new vari-
eties of foods produced by any technique, including
recombinant DNA and gene splicing processes.1
8 3
While the Council on Competitiveness appears to have had
significant involvement in establishing the former administra-
tion's policy, President Clinton recently abolished the Coun-
cil.'8 4  As a result, the future biotechnology regulatory
structure is somewhat unclear. The subject of biotechnologi-
cal regulatory processes will nevertheless almost certainly
prove to be a significant issue for the new administration.
182. Notice, 57 Fed. Reg. 22,984 (1992). In its notice, the FDA also provided
guidance for producers to follow "in determining whether their product [was] a can-
didate for food additive regulation" under § 409 of the Act and set forth criteria and
analytical steps for producers to determine "whether consultation with FDA should
be pursued to determine the regulatory status of the product." Id. at 22,990-91.
183. Id.
184. Stuart Auerbach, White House Delays Leave Regulatory Policies Hanging, WASH.
POST, Feb. 3, 1993, at FI (noting President Clinton abolished the Council on
Competitiveness).
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